Startup funding includes a Series A round led by venture capital firms Pitanga, Ecoa Capital and MOV Investimentos, along with a grant from FINEP
Following a US$ 3 million seed investment in 2022, Nintx has just raised an additional US$ 10 million. The investments will support the company’s plans for the coming years, which include accelerating the R&D of eight new drug programs, hiring researchers, introducing new technologies, and expanding the laboratory. Investors in the Series A round include venture capital firms Pitanga, Ecoa Capital and MOV Investimentos. Strategic partners Tiaraju and Adeste also invested to strengthen synergies between their businesses and Nintx. Guilherme Leal, co-founder of Natura and Dengo, and Peter Andersen, from Centroflora, remain shareholders. The Series A funds — unprecedented for a biotech startup in Brazil's pharmaceutical sector — are complemented with a grant of US$ 2.5 million by FINEP, a public company that promotes and finances science, technology and innovation. The funding coincides with a leadership restructuring at Nintx. Stephani Saverio, who co-founded the company alongside scientists Miller Freitas and Cristiano Guimarães, assumes the role of CEO in January of 2025. Previously serving on the Board of Directors, Saverio now steps into an executive role.
To have access to the full content, check us out on LinkedIn.
Comments